Mirati Therapeutics, Inc.
(NASDAQ GS: MRTX)
Rigrodsky Law, P.A. is investigating Mirati Therapeutics, Inc. (“Mirati”) regarding possible breaches of fiduciary duties and other violations of law related to Mirati’s agreement to be acquired by Bristol Myers Squibb. Under the terms of the agreement, Mirati shareholders will receive $58.00 per share in cash.